Stuart Therapeutics Spotlights Topical RP Program - Scorecard - MDSpire

Stuart Therapeutics Spotlights Topical RP Program

At OIS Retina, Eric Schlumpf discussed the company’s collagen mimetic peptide platform for retinitis pigmentosa, now in preclinical development.

  • By

  • Eric Schlumpf

  • July 15, 2026

  • 2 min

Share

Clinical Scorecard: Stuart Therapeutics Spotlights Topical RP Program

At a Glance

CategoryDetail
ConditionRetinitis Pigmentosa
Key MechanismsNeuroprotective effect, reduction of inflammation, improvement of posterior retina health
Target PopulationPatients with retinitis pigmentosa, including younger individuals
Care SettingPreclinical development

Key Highlights

  • Collagen mimetic peptide platform for retinitis pigmentosa
  • Topical therapy designed for excellent safety profile
  • Preclinical studies show drop penetration throughout the posterior retina
  • Targets critical retinal extracellular matrix region
  • Potential for treating inherited retinal disease

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Individuals with retinitis pigmentosa

          Topical therapy with potential neuroprotective effects

          Clinical Best Practices

            Related Resources & Content

              Original Source(s)

              Stuart Therapeutics Spotlights Topical RP Program

              • by Eric Schlumpf

              • July 15, 2026

              Related Content

              New Target for Uveitis Therapy

              Could targeting cGAS-STING represent a new treatment avenue for uveitis?

              • May 21, 2026

              • 3 min
              Recognizing MacTel Masquerades

              Imaging features such as retinal thinning and ellipsoid zone loss can help differentiate MacTel from AMD and related retinal diseases.

              Equal Pay in Ophthalmology? Not Yet

              A decade of AAMC salary data reveals a persistent gender pay gap in academic ophthalmology—and projects it will never close at senior ranks